Gritstone Bio Income After Taxes 2017-2024 | GRTSQ
Gritstone Bio income after taxes from 2017 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Gritstone Bio Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-138 |
| 2022 |
$-120 |
| 2021 |
$-75 |
| 2020 |
$-105 |
| 2019 |
$-94 |
| 2018 |
$-65 |
| 2017 |
$-41 |
| 2016 |
$-19 |
Gritstone Bio Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$-23 |
| 2024-03-31 |
$-40 |
| 2023-12-31 |
$-31 |
| 2023-09-30 |
$-38 |
| 2023-06-30 |
$-35 |
| 2023-03-31 |
$-34 |
| 2022-12-31 |
$-31 |
| 2022-09-30 |
$-30 |
| 2022-06-30 |
$-30 |
| 2022-03-31 |
$-29 |
| 2021-12-31 |
$-30 |
| 2021-09-30 |
$-28 |
| 2021-06-30 |
$-25 |
| 2021-03-31 |
$8 |
| 2020-12-31 |
$-27 |
| 2020-09-30 |
$-26 |
| 2020-06-30 |
$-26 |
| 2020-03-31 |
$-26 |
| 2019-12-31 |
$-28 |
| 2019-09-30 |
$-28 |
| 2019-06-30 |
$-21 |
| 2019-03-31 |
$-18 |
| 2018-12-31 |
$-17 |
| 2018-09-30 |
$-19 |
| 2018-06-30 |
$-15 |
| 2018-03-31 |
$-13 |
| 2017-12-31 |
|
| 2017-09-30 |
$-9 |
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
